- Home
- LPTX vs NVCT Comparison
LPTX vs NVCT Comparison
Compare LPTX & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NVCT
- Stock Information
- Founded
- LPTX 2011
- NVCT 2020
- Country
- LPTX United States
- NVCT United States
- Employees
- LPTX N/A
- NVCT N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- LPTX Health Care
- NVCT Health Care
- Exchange
- LPTX Nasdaq
- NVCT Nasdaq
- Market Cap
- LPTX 119.6M
- NVCT 130.6M
- IPO Year
- LPTX N/A
- NVCT 2022
- Fundamental
- Price
- LPTX $0.48
- NVCT $7.59
- Analyst Decision
- LPTX Buy
- NVCT Strong Buy
- Analyst Count
- LPTX 3
- NVCT 1
- Target Price
- LPTX $8.50
- NVCT $21.00
- AVG Volume (30 Days)
- LPTX 1.5M
- NVCT 133.8K
- Earning Date
- LPTX 03-17-2025
- NVCT 03-04-2025
- Dividend Yield
- LPTX N/A
- NVCT N/A
- EPS Growth
- LPTX N/A
- NVCT N/A
- EPS
- LPTX N/A
- NVCT N/A
- Revenue
- LPTX N/A
- NVCT N/A
- Revenue This Year
- LPTX N/A
- NVCT N/A
- Revenue Next Year
- LPTX N/A
- NVCT N/A
- P/E Ratio
- LPTX N/A
- NVCT N/A
- Revenue Growth
- LPTX N/A
- NVCT N/A
- 52 Week Low
- LPTX $0.47
- NVCT $4.44
- 52 Week High
- LPTX $4.79
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- LPTX 19.00
- NVCT 62.94
- Support Level
- LPTX $0.47
- NVCT $7.38
- Resistance Level
- LPTX $0.53
- NVCT $8.13
- Average True Range (ATR)
- LPTX 0.04
- NVCT 0.66
- MACD
- LPTX 0.07
- NVCT 0.05
- Stochastic Oscillator
- LPTX 7.42
- NVCT 76.72
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.